Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Acetone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL9790224 | 0.96 | — | — | |
| Acetone SCHEMBL2783426 | 0.96 | — | — | |
| Acetone SCHEMBL28533561 | 0.96 | LMNA (0.55) | LMNAALDH1A1TP53TSHRTDP1 | |
| Acetone SCHEMBL29098211 | 0.91 | LMNA (0.60) | LMNAALDH1A1TP53TSHRTDP1 | |
| Acetone SCHEMBL39581 | 0.91 | — | — | |
| Acetone SCHEMBL8505655 | 0.91 | LMNA (0.60) | LMNAALDH1A1TP53TSHRTDP1 | |
| Acetone SCHEMBL10768381 | 0.91 | LMNA (0.60) | LMNAALDH1A1TP53TSHRTDP1 | |
| Acetone SCHEMBL10855260 | 0.91 | LMNA (0.60) | LMNAALDH1A1TP53TSHRTDP1 | |
| Acetic Acid SCHEMBL9872942 | 0.88 | FFAR3 (0.54) | LMNAALDH1A1TP53TSHRTDP1 | |
| Acetic Acid SCHEMBL9272509 | 0.88 | FFAR3 (0.54) | LMNAALDH1A1TP53TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524476-B2 | Bacterium producing a product of a reaction catalyzed by a protein having 2-oxoglutarate-dependent enzyme activity and a method for manufacturing the product | AJINOMOTO CO., INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8367381-B2 | Method for producing 4-hydroxy-L-isoleucine | AJINOMOTO CO., INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367382-B2 | Method for producing 4-hydroxy-L-isoleucine | AJINOMOTO CO., INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120107883-A1 | METHOD FOR PRODUCING 4-HYDROXY-L-ISOLEUCINE | KODERA TOMOHIRO (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120107884-A1 | METHOD FOR PRODUCING 4-HYDROXY-L-ISOLEUCINE | KODERA TOMOHIRO (JP) | 2012-05-03 | — | — | US | disclosed |
| US-8114651-B2 | Method for producing 4-hydroxy-L-isoleucine | AJINOMOTO CO., INC. (JP) | 2012-02-14 | — | — | US | disclosed |
| WO-2011021717-A2 | METHOD FOR PRODUCING HYDROXYLATED AMINO ACIDS | AJINOMOTO CO.,INC. (JP) | 2011-02-24 | — | — | WO | disclosed |
| US-20100330622-A1 | BACTERIUM PRODUCING A PRODUCT OF A REACTION CATALYZED BY A PROTEIN HAVING 2-OXOGLUTARATE-DEPENDENT ENZYME ACTIVITY AND A METHOD FOR MANUFACTURING THE PRODUCT | AJINOMOTO CO., INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20090275092-A1 | METHOD FOR PRODUCING 4-HYDROXY-L-ISOLEUCINE | AJINOMOTO CO., INC. (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275092-A1 | METHOD FOR PRODUCING 4-HYDROXY-L-ISOLEUCINE | IL4I1, HACL2, DAO | LMNA 2569/4885ALDH1A1 807/4885TP53 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.